{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670321010311552.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1161/circulationaha.111.038943"}},{"identifier":{"@type":"URI","@value":"https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.111.038943"}}],"dc:title":[{"@value":"Acetylcysteine for Prevention of Renal Outcomes in Patients Undergoing Coronary and Peripheral Vascular Angiography"}],"dcterms:alternative":[{"@value":"Main Results From the Randomized Acetylcysteine for Contrast-Induced Nephropathy Trial (ACT)"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:sec>\n                    <jats:title>Background—</jats:title>\n                    <jats:p>It remains uncertain whether acetylcysteine prevents contrast-induced acute kidney injury.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Results—</jats:title>\n                    <jats:p>\n                      We randomly assigned 2308 patients undergoing an intravascular angiographic procedure with at least 1 risk factor for contrast-induced acute kidney injury (age >70 years, renal failure, diabetes mellitus, heart failure, or hypotension) to acetylcysteine 1200 mg or placebo. The study drugs were administered orally twice daily for 2 doses before and 2 doses after the procedure. The allocation was concealed (central Web-based randomization). All analysis followed the intention-to-treat principle. The incidence of contrast-induced acute kidney injury (primary end point) was 12.7% in the acetylcysteine group and 12.7% in the control group (relative risk, 1.00; 95% confidence interval, 0.81 to 1.25;\n                      <jats:italic>P</jats:italic>\n                      =0.97). A combined end point of mortality or need for dialysis at 30 days was also similar in both groups (2.2% and 2.3%, respectively; hazard ratio, 0.97; 95% confidence interval, 0.56 to 1.69;\n                      <jats:italic>P</jats:italic>\n                      =0.92). Consistent effects were observed in all subgroups analyzed, including those with renal impairment.\n                    </jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions—</jats:title>\n                    <jats:p>In this large randomized trial, we found that acetylcysteine does not reduce the risk of contrast-induced acute kidney injury or other clinically relevant outcomes in at-risk patients undergoing coronary and peripheral vascular angiography.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration—</jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://www.clinicaltrials.gov.\">http://www.clinicaltrials.gov</jats:ext-link>\n                      . Unique identifier: NCT00736866.\n                    </jats:p>\n                  </jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380285528933596554","@type":"Researcher","foaf:name":[{"@value":"ACT Investigators"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00097322"},{"@type":"EISSN","@value":"15244539"}],"prism:publicationName":[{"@value":"Circulation"}],"dc:publisher":[{"@value":"Ovid Technologies (Wolters Kluwer Health)"}],"prism:publicationDate":"2011-09-13","prism:volume":"124","prism:number":"11","prism:startingPage":"1250","prism:endingPage":"1259"},"reviewed":"false","url":[{"@id":"https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.111.038943"}],"createdAt":"2011-08-23","modifiedAt":"2024-05-13","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360002215302219520","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Elevation of urinary liver-type fatty acid-binding protein as predicting factor for occurrence of contrast-induced acute kidney injury and its reduction by hemodiafiltration with blood suction from right atrium"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285710425137024","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Physiological and pathophysiological role of reactive oxygen species and reactive nitrogen species in the kidney"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205224381184","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Successful Complete Revascularization With PCI Using Super-Low Volume of Contrast Medium in a Patient With Three-Vessel Disease Including 2 Chronic Total Occlusions With Severe Renal Dysfunction"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282752372831360","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Guideline on the Use of Iodinated Contrast Media in Patients With Kidney Disease 2018"},{"@value":"JCS GUIDELINES : Guideline on the Use of Iodinated Contrast Media in Patients With Kidney Disease 2018"}]},{"@id":"https://cir.nii.ac.jp/crid/2050025942143993216","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Guidelines on the use of iodinated contrast media in patients with kidney disease 2012 : digest version"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1161/circulationaha.111.038943"},{"@type":"CROSSREF","@value":"10.1007/s00380-013-0347-9_references_DOI_2TmLSA09E1V5l3M8cKdqLZKzTOF"},{"@type":"CROSSREF","@value":"10.1253/circj.cj-19-0783_references_DOI_2TmLSA09E1V5l3M8cKdqLZKzTOF"},{"@type":"CROSSREF","@value":"10.1111/1440-1681.13018_references_DOI_2TmLSA09E1V5l3M8cKdqLZKzTOF"},{"@type":"CROSSREF","@value":"10.1007/s11604-019-00850-2_references_DOI_2TmLSA09E1V5l3M8cKdqLZKzTOF"},{"@type":"CROSSREF","@value":"10.1536/ihj.16-442_references_DOI_2TmLSA09E1V5l3M8cKdqLZKzTOF"},{"@type":"CROSSREF","@value":"10.1007/s11604-013-0226-4_references_DOI_2TmLSA09E1V5l3M8cKdqLZKzTOF"}]}